• Strong cancer cell kill
  • Low toxicity for normal cells
  • Applicable to a broad spectrum of solid tumors
  • Unique dual mode of action (cell kill and anti-cancer immune response)
  • Well positioned to combine with chemo-, radio- and other immunotherapies.
  • Scalable animal component-free production process.


ORCA’s lead product ORCA-010 is derived from the common cold virus adenovirus serotype 5 (Ad5). ORCA-010 was made by modifying 3 places in the DNA of Ad5:


Through the unique combination of these modifications in the ORCA-010 product, a virus has been created that is more effective in killing cancer cells compared to competitor viruses.

Read more

Animal studies with human solid tumors have shown that ORCA-010 can stop the growth of different tumor types, and is therefore applicable to various cancer indications.

Read more

ORCA’s strategy is to first demonstrate safety and biological activity of ORCA-010 in a Phase I/II clinical trial in treatment naive patients with prostate cancer.

Read more